Author/Authors :
Kiani, Jalal Department of Virology - Faculty of Medicine - Iran University of Medical Sciences, Tehran, Iran , Javanmard, Davod Department of Virology - Faculty of Medicine - Iran University of Medical Sciences, Tehran, Iran , Ghaffari, Hadi Department of Virology - Faculty of Medicine - Iran University of Medical Sciences, Tehran, Iran , Tavakoli, Ahmad Department of Virology - Faculty of Medicine - Iran University of Medical Sciences, Tehran, Iran , Mortazavi, Helya Sadat Department of Virology - Faculty of Medicine - Iran University of Medical Sciences, Tehran, Iran , Bokharaei-Salim, Farah Department of Virology - Faculty of Medicine - Iran University of Medical Sciences, Tehran, Iran , Bangaleh, Zahra Core Laboratory - Iran University of Medical Sciences, Tehran, Iran , Monavari, Hamidreza Department of Virology - Faculty of Medicine - Iran University of Medical Sciences, Tehran, Iran
Abstract :
Background: Different outcomes of parvovirus B19 (B19V) infection in immunocompromised patients, including HIV1-infected
persons, may be life-threatening. Considering the hematologic disorders associated with B19V infection, this study aimed to investigate
the prevalence of B19V infection among HIV1-infected individuals in Iran.
Methods: Serum samples from 100 HIV1-infected patients were analyzed for B19 viral DNA using real-time PCR assay. COBAS
TaqMan HIV-1 test was performed for quantitative measurements of HIV-1 RNA in the patients’ sera.
Results: Real-time PCR analysis revealed that 10 out of 100 cases (10%) were positive for B19V infection. Across various age
groups, the B19V infection was more prevalent among patients within the age range of 21-40 years. Higher prevalence of B19V infection
was observed among HIV1-infected patients with a viral load of higher than 400 copies/mL.
Conclusion: Despite limitations, this study may set the stage for further evaluations with larger sample sizes to elucidate the potential
role of B19V in hematologic disorders, which may result in exacerbation of the disease in HIV1-infected patients. Moreover, as it
has been shown that B19V infection can be treated using intravenous immunoglobulin (IVIG) therapy, available treatments may help
improve the quality of life in HIV-infected persons.
Keywords :
AIDS , Anemia , HIV-1 , Parvovirus B19